22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors
August 19 2021 - 9:20AM
22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based,
biotechnology company focused on tobacco harm reduction, reduced
nicotine tobacco, and hemp/cannabis research, today announced the
appointment of Anthony Johnson to its Board of Directors. Mr.
Johnson is an accomplished life sciences and biotechnology
executive leader with broad expertise in corporate strategy,
technology development, marketing, and business development. Mr.
Johnson will serve as a member of the Board’s Scientific Advisory
and Compensation Committees.
“Anthony is an industry visionary in the
biotechnology field and a strategy expert in both domestic and
international capacities. He also holds extensive experience with
boards and committees, in mentoring businesses and entrepreneurs,
and in serving communities,” said 22nd Century’s Board Chair, Nora
Sullivan. “We are fortunate to welcome him to our board of
directors where we are confident his contributions will have a
significant impact on our Company’s business development,
commercialization, and value creation efforts.”
James A. Mish, chief executive officer of 22nd
Century Group, commented, “Anthony is a multi-talented business
strategist and leader with key relationships across the
pharma/biotech, diagnostic, investment banking, and funding arenas
worldwide. Having lived and worked in Europe, South America, and
the U.S., his diversity of domestic and overseas experiences will
be an instrumental resource as we execute our international
initiatives. We are excited to have Anthony join the 22nd Century
family as we build on our broad recognition as a leading
plant-based life science company.”
Mr. Johnson is co-founder, President, and CEO of
Kodikaz Therapeutic Solutions, a world-class next-generation
non-viral gene therapy company. He is also a founding partner of
Buffalo Biosciences, a life science strategic business management
firm that supports the evaluation and commercialization of
bioscience technologies from concept to market. Previously he was
president and CEO of Empire Genomics, where he transformed a
concept formed at a university lab into a preeminent oncology
molecular testing enterprise. He also served as the business leader
of the stem cell and regenerative medicine franchise for Thermo
Fisher (Invitrogen Corporation).
Mr. Johnson is an Aspen Institute Health
Innovation Fellow and a member of the Aspen Global Leadership
Network. He currently serves on the boards of several organizations
including the WNED/PBS broadcasting service of Western New York. He
has leveraged his business experience and board positions to mentor
numerous technology startups and entrepreneurs, spur state and
local job creation, and introduce STEM curriculum into early
childhood education. Mr. Johnson is also a founding board member of
the Communities of Giving Legacy Initiative, which works to create
positive change in the lives of low-income youth of color via
access to people, places, and experiences that help them achieve
their life goals. Additionally, he serves as the Michigan Street
African-American Heritage Corridor Commissioner and was an
Opportunities Council member for the University of Buffalo.
Formerly, he was a 15-year volunteer with the Big Brother Big
Sister Foundation. Mr. Johnson holds an MBA from Manchester
Business School, Manchester, UK, with an emphasis in international
strategy, and a BA in biology from Fisk University, Nashville,
TN.
About 22nd Century
Group, Inc.22nd Century Group, Inc.
(Nasdaq: XXII) is a leading plant biotechnology company
focused on technologies that alter the level of nicotine in tobacco
plants and the level of cannabinoids in hemp/cannabis plants
through genetic engineering, gene editing, and modern plant
breeding. 22nd Century’s primary mission in tobacco is to reduce
the harm caused by smoking through the Company’s reduced nicotine
content tobacco cigarettes – containing 95% less nicotine than
conventional cigarettes. The Company’s primary mission in
hemp/cannabis is to develop and commercialize proprietary
hemp/cannabis plants with valuable cannabinoid profiles and
desirable agronomic traits.
Learn more at xxiicentury.com, on
Twitter @_xxiicentury, and on LinkedIn.
Cautionary Note Regarding
Forward-Looking StatementsExcept for historical
information, all of the statements, expectations, and assumptions
contained in this press release are forward-looking statements.
Forward-looking statements typically contain terms such as
“anticipate,” “believe,” “consider,” “continue,” “could,”
“estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,”
“intend,” “likely,” “may,” “plan,” “potential,” “predict,”
“preliminary,” “probable,” “project,” “promising,” “seek,”
“should,” “will,” “would,” and similar expressions. Actual results
might differ materially from those explicit or implicit in
forward-looking statements. Important factors that could cause
actual results to differ materially are set forth in “Risk Factors”
in the Company’s Annual Report on Form 10-K filed on March 11,
2021. All information provided in this release is as of the date
hereof, and the Company assumes no obligation to and does not
intend to update these forward-looking statements, except as
required by law.
Investor Relations & Media
Contact:Mei KuoDirector, Communications & Investor
Relations22nd Century Group, Inc.(716)
300-1221mkuo@xxiicentury.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/16ae6d2c-57ef-4b94-b510-659097fc0377
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From Sep 2023 to Sep 2024